SLC5A2 and atrial fibrillation: Li et al. systematically reviewed 16 RCTs encompassing 38,335 patients and confirmed the efficacy of SGLT2 inhibitors in reducing AF and atrial flutter (RR: 0.76; 95% CI: 0.65–0.90) [17].